Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Bexxar enters phase II trial for intermediate-grade NHL

July 28, 2000

Potent new inhibitor of p210Bcr-Abl tyrosine kinase with selectivity for Bcr-Abl-positive leukemia

July 28, 2000

Synergism reported by Aventis for combination chemotherapies

July 27, 2000

ABX-EGF will be codeveloped by Abgenix and Immunex

July 27, 2000

Protegrin IB-367 progresses through clinical development for the palliation of mucositis

July 27, 2000

Licensing opportunity from NIH: newly isolated cancer therapy target gene

July 26, 2000

Paladin to market Aptosyn in Canada

July 26, 2000

Taiho's novel anticancer therapy licensed to SB

July 26, 2000

Genasense shown to enhance activity of chemotherapy in mouse model of breast cancer

July 26, 2000

Galenica and Memorial Sloan-Kettering initiate phase I trial of prostate cancer treatment

July 26, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...